TH171908A - Therapeutic constituents containing rilpivirine HCL (rilpivirine HCL) and tenofovir disoproxil fumarate (tenofovir disoproxil fumarate). - Google Patents
Therapeutic constituents containing rilpivirine HCL (rilpivirine HCL) and tenofovir disoproxil fumarate (tenofovir disoproxil fumarate).Info
- Publication number
- TH171908A TH171908A TH1301002632A TH1301002632A TH171908A TH 171908 A TH171908 A TH 171908A TH 1301002632 A TH1301002632 A TH 1301002632A TH 1301002632 A TH1301002632 A TH 1301002632A TH 171908 A TH171908 A TH 171908A
- Authority
- TH
- Thailand
- Prior art keywords
- tenofovir disoproxil
- disoproxil fumarate
- hci
- rilpivrine
- rilpivirine hcl
- Prior art date
Links
- 229960004693 Tenofovir disoproxil fumarate Drugs 0.000 title claims abstract 12
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 title claims abstract 12
- 229960002814 rilpivirine Drugs 0.000 title claims 4
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 title claims 4
- 239000000470 constituent Substances 0.000 title 1
- 230000001225 therapeutic Effects 0.000 title 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N (2R-cis)-4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-Pyrimidinone Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims abstract 6
- 229960000366 emtricitabine Drugs 0.000 claims abstract 5
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims abstract 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960004481 rilpivirine hydrochloride Drugs 0.000 claims abstract 2
- KZVVGZKAVZUACK-BJILWQEISA-N rilpivirine hydrochloride Chemical compound Cl.CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 KZVVGZKAVZUACK-BJILWQEISA-N 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Abstract
DC60 (31/05/56) การประดิษฐ์ได้จัดให้มียาเม็ดแบนหลายชั้นที่ประกอบด้วย ริลพิวิรีน ไฮโดรคลอไรด์ (rilpivrine HCI), เอมไตรซิทาบีน (emtricitabine), และ เทโนโฟเวียร์ ไดโซพรอกซิล ฟิวมาเรต (tenofovir disoproxil fumarate) ยาเม็ดแบนนั้นเป็นประโยชน์สำหรับการบำบัดของ HIV การประดิษฐ์ได้จัดให้มียาเม็ดแบบหลายชั้นทีประกอบด้วย ริลพิวิรีน ไฮโดรคลอไรด์ (rilpivrine HC1), เอมไตรซิทาบีน (emtricitabine), และ เทโนโฟเวียร์ ไดโซพรอกซิล ฟิวมาเรต (tenofovir disoproxil fumarate) ยาเม็ดแบนนั้นเป็นประโยชน์สำหรับการบำบัดของ HIV สิทธิบัตรยา DC60 (31/05/56) The invention provides a multi-layered, flat tablet containing rilpivrine hydrochloride (rilpivrine HCI), emtrisitabine. (emtricitabine), and tenofovir disoproxil fumarate (tenofovir disoproxil fumarate), flat tablets are useful for the treatment of HIV. Contains rilpivirine hydrochloride (rilpivrine HC1), emtrisitabine. (emtricitabine), and tenofovir disoproxil fumarate (tenofovir disoproxil fumarate) flat tablets are useful for HIV therapy.
Claims (2)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TH171908A true TH171908A (en) | 2017-12-28 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19078196A (en) | THERAPEUTIC COMPOSITIONS INCLUDING RILPIVIRINE HCL AND TENOFOVIR DISOPROXIL FUMARATE | |
| NL300768I2 (en) | Combination of rilpivirine or a pharmaceutically acceptable salt of rilpivirine, including the hydrochloride salt of rilpivirine, tenofovir disoproxil fumarate, and emtricitabine | |
| MY191357A (en) | Sustained-release dosage forms of ruxolitinib | |
| WO2012131463A3 (en) | Controlled release pharmaceutical dosage forms | |
| EA201201263A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING DAGIGATRAN ETEXYLATE | |
| JP2015057451A5 (en) | ||
| SG194756A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
| MY163809A (en) | Transdermal drug delivery system containing donepezil | |
| EA201390977A1 (en) | COMBINATION OF OPIOID RECEPTOR AGONIST AND OPIOID RECEPTOR ANTAGONIST FOR THE TREATMENT OF PARKINSON'S Disease | |
| EP3513789A3 (en) | Prophylactic and therapeutic agents for fgfr3 diseases | |
| RS54244B1 (en) | Nalbuphine-based formulations and uses thereof | |
| CY1110097T1 (en) | DOUBLE-TESTED DISC FOR PREVENTING HEALTHCARE | |
| EA201201202A1 (en) | ORAL PHARMACEUTICAL COMPOSITION CONTAINING DABIGATRANE EXTILE | |
| CL2014001534A1 (en) | Fixed dose combination comprising benazepril hydrochloride and pimobendan in the form of a two-layer tablet; manufacturing procedure and use in the treatment of congestive heart failure in dogs. | |
| MY166972A (en) | Transdermal delivery system containing galantamine or salts thereof | |
| TH171908A (en) | Therapeutic constituents containing rilpivirine HCL (rilpivirine HCL) and tenofovir disoproxil fumarate (tenofovir disoproxil fumarate). | |
| CY1116115T1 (en) | THERAPEUTIC COMPOSITIONS CONTAINED BY RILPIVIRIN HCL AND DIOPROXILIC FENO TENOPHOIR | |
| NO2017066I1 (en) | Combination of rilpivirine hydrochloride or its therapeutic equivalent, tenofovir, especially tenofovir disproxil fumarate, and emtricitabine | |
| CY1121354T1 (en) | METHODS OF TREATMENT OR PREVENTION OF ASTHMA THROUGH IL-4R COMPETITOR | |
| MX2010006317A (en) | Oral pharmaceutical composition with an antihistamine and decongestant. | |
| CN302039017S (en) | Chair (111226) | |
| CN302310402S (en) | Medication patch (golden cold method) | |
| CN301973799S (en) | Mattress (HY-HX) | |
| CN302360136S (en) | Infusion Monitor (Medical) | |
| CN302089030S (en) | Chair (HLP-5118) |